PKD1 is critical for Epstein–Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab

References

• Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502–506.
   PubMed Web of Science ®Google Scholar
• Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006;85:463–468.
   PubMed Web of Science ®Google Scholar
• Griffin BE. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. Mutat Res 2000;462:395–405.
   PubMedGoogle Scholar
• Fåhraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329–338.
   PubMed Web of Science ®Google Scholar
• Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769–774.
   PubMed Web of Science ®Google Scholar
• Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80: 389–399.
   PubMed Web of Science ®Google Scholar
• Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997;16:6131–6140.
   PubMed Web of Science ®Google Scholar
• Mcfarland EDC, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NFkB. Oncogene 1999;19:6959–6964.
   Web of Science ®Google Scholar
• Kim JH, Kim WS, Kang JH, et al. Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. FEBS Lett 2007;581:623–628.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim WS, Park C. SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. Leuk Lymphoma 2008;49:1392–1398.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim WS, Yun Y, et al. Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cell Signal 2010;22:1858–1863.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma 2012;53:1586–1591.
   PubMed Web of Science ®Google Scholar
• LaValle CR, George KM, Sharlow ER, et al. Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta 2010;1806:183–192.
   PubMed Web of Science ®Google Scholar
• Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci 2006;27:317–323.
   PubMed Web of Science ®Google Scholar
• Van Lint J, Rykx A, Maeda Y, et al. Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol 2002;12:193–200.
   PubMedGoogle Scholar
• Nishio S, Hatano M, Nagata M, et al. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 2005;115:910–918.
   PubMed Web of Science ®Google Scholar
• Storz P, Toker A. Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway. EMBO J 2003;22:109–120.
   PubMed Web of Science ®Google Scholar
• Trauzold A, Schmiedel S, Sipos B, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003;22:8939–8947.
   PubMed Web of Science ®Google Scholar
• Storz P, Döppler H, Toker A. Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappaB. Mol Pharmacol 2004;66:870–879.
   PubMed Web of Science ®Google Scholar
• Guo B, Su TT, Rawlings DJ. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004;16:367–373.
   PubMed Web of Science ®Google Scholar
• Storz P, Döppler H, Toker A. Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling. Mol Cell Biol 2004;24:2614–2626.
   PubMed Web of Science ®Google Scholar
• Storz P, Döppler H, Johannes FJ, et al. Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain leads to activation. J Biol Chem 2003;278:17969–17976.
   PubMedGoogle Scholar
• Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003;10:490–504.
   PubMed Web of Science ®Google Scholar
• Endo K, Kondo S, Shackleford J, et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 2009;28: 1725–1735.
   PubMed Web of Science ®Google Scholar
• Luo W, Yan G, Li L, et al. Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCalpha/PKCbeta pathway. Mol Carcinog 2008;47:934–946.
   PubMed Web of Science ®Google Scholar
• Baron CL, Malhotra V. Role of diacylglycerol in PKD recruitment to the TGN and protein transport to the plasma membrane. Science 2002;295:325–328.
   PubMedGoogle Scholar
• Matthews SA, Iglesias T, Rozengurt E, et al. Spatial and temporal regulation of protein kinase D (PKD). EMBO J 2000;19:2935–2945.
   PubMed Web of Science ®Google Scholar
• Rey O, Young SH, Cantrell D, et al. Rapid protein kinase D translocation in response to G protein-coupled receptor activation. Dependence on protein kinase C. J Biol Chem 2001;276: 32616–32626.
   Google Scholar
• Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775–1782.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705–3714.
   PubMed Web of Science ®Google Scholar
• van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010;47:199–210.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115–123.
   PubMed Web of Science ®Google Scholar
• Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629–3636.
   PubMed Web of Science ®Google Scholar